Active, currently enrolling
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
NCT No.: NCT03898479
Study Type: INTERVENTIONAL
Phase:
Phase II
Region: California - Northern
Acronym: CTP-543
Official Title
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
Purpose
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Detailed Description
Eligibility Criteria
Inclusion Criteria
|
Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial.
|
Exclusion Criteria
|
Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis.
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication.
Donation of blood at any point throughout the study and for 30 days after last dose of study medication.
|
Keywords and/or Specific Medical Conditions
|
|
|
|
|
|
|
|
|
|
-
Pathological Conditions, Anatomical
|
|
|
|
|
|
|
Sponsors
|